Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Overview of attention for article published in Clinical Cancer Research, March 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 3 news outlets

twitter: 46 X users

Readers on

mendeley: 74 Mendeley

So far, Altmetric has seen 55 X posts from 46 X users, with an upper bound of 173,522 followers.

RT @CCR_AACR: ZUMA-7 Analysis: Axi-Cel in Patients ≥65 Years With R/R LBCL. https://t.co/gVyL45DdiC https://t.co/zpysgnZ5so

ZUMA-7 Analysis: Axi-Cel in Patients ≥65 Years With R/R LBCL. https://t.co/gVyL45DdiC https://t.co/zpysgnZ5so

Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma - PMC- Full text out, congrats ⁦@MattUlricksonMD⁩ https://t.co/e0I1S4hMYu

@robertlown https://t.co/kbV3XCqOTe

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 51 additional X posts.